CN115666720A - 用于治疗肾病的cer-001疗法 - Google Patents
用于治疗肾病的cer-001疗法 Download PDFInfo
- Publication number
- CN115666720A CN115666720A CN202180035372.6A CN202180035372A CN115666720A CN 115666720 A CN115666720 A CN 115666720A CN 202180035372 A CN202180035372 A CN 202180035372A CN 115666720 A CN115666720 A CN 115666720A
- Authority
- CN
- China
- Prior art keywords
- cer
- regimen
- subject
- dose
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063011048P | 2020-04-16 | 2020-04-16 | |
US63/011,048 | 2020-04-16 | ||
US202063092072P | 2020-10-15 | 2020-10-15 | |
US63/092,072 | 2020-10-15 | ||
IBPCT/IB2021/000021 | 2021-01-07 | ||
PCT/IB2021/000021 WO2021209808A1 (en) | 2020-04-16 | 2021-01-07 | Cer-001 therapy for treating kidney disease |
PCT/IB2021/000282 WO2021209822A1 (en) | 2020-04-16 | 2021-04-15 | Cer-001 therapy for treating kidney disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115666720A true CN115666720A (zh) | 2023-01-31 |
Family
ID=76034906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180035372.6A Pending CN115666720A (zh) | 2020-04-16 | 2021-04-15 | 用于治疗肾病的cer-001疗法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US11752163B2 (ko) |
EP (1) | EP4135838A1 (ko) |
JP (1) | JP2023522055A (ko) |
KR (1) | KR20230004606A (ko) |
CN (1) | CN115666720A (ko) |
AU (1) | AU2021254856A1 (ko) |
CA (1) | CA3177735A1 (ko) |
IL (1) | IL297046A (ko) |
MX (1) | MX2022012906A (ko) |
WO (1) | WO2021209822A1 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021254856A1 (en) | 2020-04-16 | 2022-11-10 | Abionyx Pharma Sa | CER-001 therapy for treating kidney disease |
WO2023194798A1 (en) * | 2022-04-06 | 2023-10-12 | Abionyx Pharma Sa | Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes |
WO2023237927A2 (en) * | 2022-06-10 | 2023-12-14 | Abionyx Pharma Sa | Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes |
WO2023237935A2 (en) * | 2022-06-10 | 2023-12-14 | Abionyx Pharma Sa | Methods for treating acute conditions using lipid binding protein-based complexes |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5932536A (en) | 1994-06-14 | 1999-08-03 | The Rockefeller University | Compositions for neutralization of lipopolysaccharides |
US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
WO2004010939A2 (en) | 2002-07-30 | 2004-02-05 | Esperion Therapeutics, Inc. | Methods of using non-human animal apoliprotein a-i protein |
US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
RU2532222C2 (ru) | 2009-02-16 | 2014-10-27 | Серенис Терапьютикс Холдинг С.А, | Миметики аполипопротеина а-i |
PL2767546T3 (pl) | 2011-02-07 | 2019-04-30 | Cerenis Therapeutics Holding Sa | Kompleksy lipoproteinowe i ich wytwarzanie oraz ich zastosowania |
WO2012135046A1 (en) | 2011-03-25 | 2012-10-04 | The Trustees Of Columbia University In The City Of New York | Pegylated human hdl particle and process for production thereof |
US20140316154A1 (en) | 2013-03-15 | 2014-10-23 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
EP2853259A1 (en) | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
US20150316566A1 (en) * | 2014-05-02 | 2015-11-05 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
US10517924B2 (en) | 2014-11-24 | 2019-12-31 | Northwestern University | High density lipoprotein nanoparticles for inflammation |
WO2018022511A1 (en) | 2016-07-25 | 2018-02-01 | The Trustees Of The University Of Pennsylvania | Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof |
EP3490579A1 (en) | 2016-07-27 | 2019-06-05 | Hartis-Pharma SA | Therapeutic combinations to treat red blood cell disorders |
WO2018029505A1 (en) | 2016-08-11 | 2018-02-15 | Cerenis Therapeutics Holding Sa | Cer-001 therapy for treating familial primary hypoalphalipoproteinemia |
FR3100715B1 (fr) | 2019-09-12 | 2023-09-29 | Francais Du Sang Ets | Utilisation de HDL dans la prophylaxie de la maladie du greffon contre l’hôte |
WO2021209808A1 (en) | 2020-04-16 | 2021-10-21 | Abionyx Pharma Sa | Cer-001 therapy for treating kidney disease |
AU2021254856A1 (en) | 2020-04-16 | 2022-11-10 | Abionyx Pharma Sa | CER-001 therapy for treating kidney disease |
AU2021256086A1 (en) | 2020-04-16 | 2022-12-15 | Abionyx Pharma Sa | Methods for treating acute conditions using lipid binding protein- based complexes |
-
2021
- 2021-04-15 AU AU2021254856A patent/AU2021254856A1/en active Pending
- 2021-04-15 IL IL297046A patent/IL297046A/en unknown
- 2021-04-15 CA CA3177735A patent/CA3177735A1/en active Pending
- 2021-04-15 US US17/231,659 patent/US11752163B2/en active Active
- 2021-04-15 WO PCT/IB2021/000282 patent/WO2021209822A1/en unknown
- 2021-04-15 EP EP21726966.1A patent/EP4135838A1/en active Pending
- 2021-04-15 MX MX2022012906A patent/MX2022012906A/es unknown
- 2021-04-15 CN CN202180035372.6A patent/CN115666720A/zh active Pending
- 2021-04-15 KR KR1020227039570A patent/KR20230004606A/ko active Search and Examination
- 2021-04-15 JP JP2022562977A patent/JP2023522055A/ja active Pending
-
2023
- 2023-07-21 US US18/356,280 patent/US20240016824A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023522055A (ja) | 2023-05-26 |
CA3177735A1 (en) | 2021-10-21 |
MX2022012906A (es) | 2023-03-14 |
AU2021254856A1 (en) | 2022-11-10 |
US11752163B2 (en) | 2023-09-12 |
US20240016824A1 (en) | 2024-01-18 |
KR20230004606A (ko) | 2023-01-06 |
US20210322448A1 (en) | 2021-10-21 |
WO2021209822A1 (en) | 2021-10-21 |
IL297046A (en) | 2022-12-01 |
EP4135838A1 (en) | 2023-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115666720A (zh) | 用于治疗肾病的cer-001疗法 | |
Panichi et al. | The link of biocompatibility to cytokine production | |
WO2021209808A1 (en) | Cer-001 therapy for treating kidney disease | |
US8048015B2 (en) | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content | |
US20180355021A1 (en) | Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content | |
Parolini et al. | Infusions of large synthetic HDL containing trimeric apoA-I stabilize atherosclerotic plaques in hypercholesterolemic rabbits | |
US20040106556A1 (en) | Method of treating and preventing alzheimer disease through administration of delipidated protein and lipoprotein particles | |
IL297114A (en) | Preparations that include 15-hepe for the treatment or prevention of hematological disorders, and/or related diseases | |
Aboshahba et al. | New Trends Approved in Management of Dyslipidaemia | |
Bawakhan | Association Between Nutritional Indicators and Hemodialysis Adequacy in End Stage Renal Disease Patients Attending Nephrology Unit in Kims, Hubli | |
JP2006160757A (ja) | 脂質代謝異常治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |